DRUG
Desmopressin Acetate
This arm will receive tamsulosin and desmopressin acetate daily a
Adding Desmopressin to Tamsulosin for Treatment of BPH
Status
Unknown
Phase
Phase 4
Enrollment
160
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
In this study investigators will add desmopressin for treatment of patients with benign prostatic hyperplasia and nocturnal polyurea
Full detailed description
Investigators will give a group of patients tamsulosin and desmopressin and the other group will take tamsulosin and placepo and compare the outcome regarding symptoms of being prostatic hyperplasia especially nocturia and the effect on nocturnal polyurea in patients
Interventions
Treatment arms and agents.
DRUG
Placebo
This arm will receive tamsulosin and placebo
Timeline
From registration to results.
First posted
Jul 14, 2023
Study start
Jul 20, 2023
Primary completion
Jan 10, 2024
Study completion
Feb 10, 2024
Results posted
Not reported
Registry updated
Jul 14, 2023
Outcomes
What the study measures.
Primary outcomes
Change of symptoms and nocturia disappears or improve
Time frame · Follow up for 6 months
Investigators will compare symptoms in the pretreatment period and follow up symptoms following treatment and record the outcome
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 50 Years
- Maximum age
- 80 Years
- Sex
- MALE
- Healthy volunteers
- Yes
Inclusion Criteria: Men with BPH Age more than 50years Patients with nocturia (2voids per night or More) Patients with nocturnal polyurea (urine volume More than 33%of urine allover the day) IPSS more than 12 Obstructed flow curve Post voiding residual less than 150 Exclusion Criteria: * men with BPH with : Acute urine retention Neurogenic bladder dysfunction Cardiovascular disease Hyponatremia Urethral stricture Bladder calculi Prostate cancer
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Urology and nephrology center
Al Mansurah, Outside U.S./Canada, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Desmopressin.
NCT IDStudyPhase / statusEnrollmentUpdated
Randomized Controlled Clinical Study on the Prophylactic Intraoperative Use of Desmopressin in Complex Sellar Region Tumors
Zhaoyun Zhang · Craniopharyngiomas · Pituitary Macroadenoma
Phase 4
Enrolling by invitation
152
2026-07
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Cushing Syndrome
Phase 2
Recruiting
140
2026-07
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
Hamilton Health Sciences Corporation · Chronic Kidney Diseases · Acute Kidney Injury
Phase 3
Recruiting
100
2026-05
International Multi-center Retrospective Study of Patients With Serum Sodium ≤110 mmol/L to Determine the Relationship Between Osmotic Demyelination Syndrome (ODS) and Rapid Correction of Hyponatremia
Rochester General Hospital · Hyponatremia Symptomatic · Osmotic Demyelination Syndrome
Not applicable
Enrolling by invitation
800
2026-05
DDAVP for Pituitary Adenoma
National Institute of Neurological Disorders and Stroke (NINDS) · Cushing's Disease · Pituitary Adenoma
Not applicable
Recruiting
22
2026-04
Vitamin D Versus Desmopressin Versus Combination Therapy in Children With Primary Monosymptomatic Nocturnal Enuresis and Vitamin D Deficiency
Ain Shams University · Nocturnal Enuresis · Vitamin D Deficiency
Not applicable
Completed
90
2026-03
Ginkgo Biloba vs Desmopressin in Treatment of Children With Monosymptomatic Nocturnal Enuresis
Menoufia University · Nocturnal Enuresis in Children · Desmopressin
Not applicable
Completed
398
2026-01
NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden
Ferring Pharmaceuticals · Adverse Drug Event
Not applicable
Completed
1,099,551
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.